Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group. Oriol A, et al. Among authors: guardia r. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145276 Free PMC article.
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E; CETLAM AML-99. Oriol A, et al. Among authors: guardia r. Haematologica. 2004 Jul;89(7):791-800. Haematologica. 2004. PMID: 15257930 Clinical Trial.
Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM, Bargay J, Guardia R, Juliá A, Granena A, Montserrat E, Sierra J; Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias. Brunet S, et al. Among authors: guardia r. Haematologica. 2004 Aug;89(8):940-9. Haematologica. 2004. PMID: 15339677 Clinical Trial.
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E. Ribera JM, et al. Among authors: guardia r. J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21. J Clin Oncol. 2014. PMID: 24752047 Clinical Trial.
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.
Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Orfao A, Ribera JM. Barba P, et al. Among authors: guardia r. Eur J Haematol. 2019 Jan;102(1):79-86. doi: 10.1111/ejh.13178. Epub 2018 Nov 22. Eur J Haematol. 2019. PMID: 30267597 Clinical Trial.
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E. Salar A, et al. Among authors: guardia r. Haematologica. 2002 Oct;87(10):1028-35. Haematologica. 2002. PMID: 12368156
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.
Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E, Sierra J; CETLAM. Monzo M, et al. Among authors: guardia r. Blood. 2006 Jun 15;107(12):4871-9. doi: 10.1182/blood-2005-08-3272. Epub 2006 Feb 28. Blood. 2006. PMID: 16507781 Free article. Clinical Trial.
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ; CETLAM Group. Valcárcel D, et al. Among authors: guardia r. Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717435 Free article.
Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia.
Barba P, Martino R, Martinez-Cuadron D, Olga G, Esquirol A, Gil-Cortés C, Gonzalez J, Fernandez-Avilés F, Valcárcel D, Guardia R, Duarte RF, Hernandez-Rivas JM, Abella E, Montesinos P, Ribera JM. Barba P, et al. Among authors: guardia r. Leuk Lymphoma. 2015;56(10):2812-8. doi: 10.3109/10428194.2015.1014365. Epub 2015 Mar 6. Leuk Lymphoma. 2015. PMID: 25686647
73 results